Literature DB >> 25945585

The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine.

Marina Alexeeva1, Espen Åberg1, Richard A Engh1, Ulli Rothweiler1.   

Abstract

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a protein kinase associated with neuronal development and brain physiology. The DYRK kinases are very unusual with respect to the sequence of the catalytic loop, in which the otherwise highly conserved arginine of the HRD motif is replaced by a cysteine. This replacement, along with the proximity of a potential disulfide-bridge partner from the activation segment, implies a potential for redox control of DYRK family activities. Here, the crystal structure of DYRK1A bound to PKC412 is reported, showing the formation of the disulfide bridge and associated conformational changes of the activation loop. The DYRK kinases represent emerging drug targets for several neurological diseases as well as cancer. The observation of distinct activation states may impact strategies for drug targeting. In addition, the characterization of PKC412 binding offers new insights for DYRK inhibitor discovery.

Entities:  

Keywords:  DYRK kinase; PKC412; disulfide bridge; inhibitor; midostaurin; redox

Mesh:

Substances:

Year:  2015        PMID: 25945585     DOI: 10.1107/S1399004715005106

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  7 in total

1.  ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.

Authors:  Beth Apsel Winger; Wilian A Cortopassi; Diego Garrido Ruiz; Lucky Ding; Kibeom Jang; Ariel Leyte-Vidal; Na Zhang; Rosaura Esteve-Puig; Matthew P Jacobson; Neil P Shah
Journal:  Cancer Res       Date:  2019-07-03       Impact factor: 12.701

2.  The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.

Authors:  Timothy T Ferng; Daisuke Terada; Makoto Ando; Theodore C Tarver; Fihr Chaudhary; Kimberly C Lin; Aaron C Logan; Catherine C Smith
Journal:  Mol Cancer Ther       Date:  2022-05-04       Impact factor: 6.261

Review 3.  Impact of the Protein Data Bank on antineoplastic approvals.

Authors:  John D Westbrook; Rose Soskind; Brian P Hudson; Stephen K Burley
Journal:  Drug Discov Today       Date:  2020-02-14       Impact factor: 7.851

4.  Functional characterization of DYRK1A missense variants associated with a syndromic form of intellectual deficiency and autism.

Authors:  Esti Wahyu Widowati; Sabrina Ernst; Ralf Hausmann; Gerhard Müller-Newen; Walter Becker
Journal:  Biol Open       Date:  2018-04-26       Impact factor: 2.422

5.  Pocket2Drug: An Encoder-Decoder Deep Neural Network for the Target-Based Drug Design.

Authors:  Wentao Shi; Manali Singha; Gopal Srivastava; Limeng Pu; J Ramanujam; Michal Brylinski
Journal:  Front Pharmacol       Date:  2022-03-11       Impact factor: 5.810

Review 6.  Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome.

Authors:  Helin Atas-Ozcan; Véronique Brault; Arnaud Duchon; Yann Herault
Journal:  Genes (Basel)       Date:  2021-11-20       Impact factor: 4.096

Review 7.  Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.

Authors:  Mattias F Lindberg; Laurent Meijer
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.